Clinical trials: Haemostatic
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004107
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Multiple Myeloma, Cast Nephropathy
European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy
Hypothesis: Free light chain removal haemodialysis will increase the rate of renal recovery in patients with cast nephropathy, severe renal failure and de novo multiple myeloma.
- Conditions
- Multiple Myeloma, Cast Nephropathy, Kidney Failure
- Trial name
- EuLITE (NCT00700531)
- Testing
- FLC removal HD (Gambro HCO 1100), Standard dialysis on a high flux ployflux dialyser
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University Hospital Birmingham
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
This phase I trial tests the effect of allogeneic Orca-Q stem cell transplant in treating patients with high-risk multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous…
- Trial name
- NCT07759102
- Testing
- Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Multiple Myeloma
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
The outcomes in patients with relapsed or refractory multiple myeloma refractory to triple-therapy remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous…
- Trial name
- NCT07200102
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma
This is a single-arm, non-randomized, open-label study to confirm the RP2D (recommended phase 2 dose) of GC012F injection in patients with Relapsed/Refractory multiple myeloma (RRMM).
- Trial name
- NCT05412329
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Changzheng Hospital
Abdominal Aortic Aneurism, Abdominal Aortic Rupture
Haemostasis Management of Abdominal Aortic Procedures
Comparative study on efficacy of haemostatic therapy guided either by standard laboratory coagulation parameters or point-of-care testing in patients undergoing vascular surgical procedures.
- Conditions
- Abdominal Aortic Aneurism, Abdominal Aortic Rupture, Perioperative/Postoperative Complications, Surgical Blood Loss
- Trial name
- NCT03426839
- Testing
- Coagulation tests
- Volunteers
- 40 people
- Sponsor
- University of Pecs
Relapsed/Refractory Multiple Myeloma (RRMM)
A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of GPRC5D/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with…
- Trial name
- QLS32015 (NCT07185477)
- Testing
- QLS32015
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Arterial Occlusion, Cardiovascular Diseases
Comparing Perclose to Statseal in Conjunction With Perclose in Femoral 6 French Arteriotomy Closure
The purpose of this clinical study is to compare how well two different devices for achieving hemostasis perform in patients undergoing transfemoral procedures with 6 French Access.
- Conditions
- Arterial Occlusion, Cardiovascular Diseases, Atherosclerosis, Hematoma
- Trial name
- NCT05468957
- Testing
- Perclose, Statseal
- Where
- 2 sites in United States
- Sponsor
- University of California, Los Angeles
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
EHealth Educational Intervention to Improve Self-Management and Coping Behaviors Among Cancer Patients
Brief Summary This study evaluates the effectiveness of a structured eHealth-based educational and support intervention in improving self-management practices and psychological coping behaviors among adult cancer patients.
- Trial name
- EHCancer (NCT07457112)
- Testing
- Structured eHealth Educational Intervention
- Where
- Egypt
- Volunteers
- 212 people
- Sponsor
- Zagazig University
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding…
- Trial name
- NCT03850730
- Testing
- Pazopanib
- Volunteers
- 30 people
- Sponsor
- Cure HHT
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with…
- Trial name
- LINKER-MM4 (NCT05828511)
- Testing
- Linvoseltamab
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Waldenström Macroglobulinemia
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
This phase I/II trial is studying the side effects and best dose of oblimersen and to see how well it works in treating patients with relapsed or refractory Waldenstrom's macroglobulinemia.
- Trial name
- NCT00062244
- Testing
- oblimersen sodium
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01816971
- Testing
- dexamethasone, carfilzomib, lenalidomide
- Where
- 5 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- University of Chicago
Multiple Myeloma
Virtual Exercise for Multiple Myeloma
The primary objective of this pilot study is to determine the safety and feasibility a 12-week virtually supported home-based aerobic and resistance exercise program progressing cancer survivors with Multiple Myeloma to meet…
- Trial name
- MY-PROGRESS (NCT04484714)
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- University of Alberta
Multiple Myeloma, Plasma Cell Neoplasm
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Trial name
- NCT00028600
- Testing
- filgrastim, CD34+ cells, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
The purpose of the study is to compare thalidomide + dexamethasone with bortezomib + dexamethasone in patients with multiple myeloma refractory to melphalan therapy.
- Trial name
- NCT00602511
- Testing
- Bortezomib, Thalidomide
- Where
- 27 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Nordic Myeloma Study Group
Multiple Myeloma
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.
- Trial name
- 2007-77 (NCT00657553)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Telangiectasia, Hereditary Hemorrhagic, Intracranial Arteriovenous Malformations
Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database
With a described prevalence of brain arteriovenous malformations (CAVM) of 12.8% in HHT patients, of whom 10% presents with intracranial hemorrhage, HHT pose a risk of devastating intracranial hemorrhage.
- Trial name
- DAN-HEMTEL-VM (NCT05933330)
- Testing
- Brain MRI
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Odense University Hospital